REDDING, Calif. , Aug. 19, 2024 /PRNewswire/ -- According to a new market research report titled, " Real-world Evidence Solutions Market Size, Share, Forecast, & Trends Analysis by Component (Datasets [Clinical, Claims, Pharmacy], Services) Application (Market Access, Drug Development & Approvals, PMS) End User—Global Forecast to 2031", published by Meticulous Research ® , the real-world evidence solutions market was valued at $2.
62 billion in 2023. This market is expected to reach $6.37 billion by 2031 from an estimated $2.
94 billion in 2024, at a CAGR of 11.7% during the forecast period of 2024-2031. Download Sample Report Now- https://www.
meticulousresearch.com/download-sample-report/cp_id=4954 Clinical evidence obtained from the examination of real-world data (RWD) is known as real-world evidence (RWE). The resulting clinical evidence covers the use of a medical product and its possible advantages or disadvantages.
Pharmaceutical, biotechnology, and medical device firms, as well as healthcare payers and providers, employ RWE solutions for market access and reimbursement/coverage choices, drug development and approvals, post-market surveillance, and medical device development and approvals. The market for RWE solutions is expanding due to various causes such as the increasing prevalence of chronic illnesses, the growing emphasis on personalized healthcare, the transition to value-based care, and the increasing use of real-world evidence solutions in drug development and.